%0 Journal Article
%T Guidelines of the Brazilian Society of Surgical Oncology for anatomopathological, immunohistochemical, and molecular testing in female tumors.
%A Ribeiro R
%A Carvalho FM
%A Baiocchi G
%A Guindalini RSC
%A da Cunha JR
%A Anjos CHD
%A de Nadai Costa C
%A Gifoni ACLVC
%A Neto RC
%A Cagnacci AQC
%A Carneiro VCG
%A Calabrich A
%A Moretti-Marques R
%A Pinheiro RN
%A de Castro Ribeiro HS
%J J Surg Oncol
%V 0
%N 0
%D 2024 Jul 22
%M 39038206
%F 2.885
%R 10.1002/jso.27717
%X <B>BACKGROUND: </B>Precision medicine has revolutionized oncology, providing more personalized diagnosis, treatment, and monitoring for patients with cancer. In the context of female-specific tumors, such as breast, ovarian, endometrial, and cervical cancer, proper tissue collection and handling are essential for obtaining tissue, immunohistochemical (IHC), and molecular data to guide therapeutic decisions.<BR><B>OBJECTIVE: </B>To establish guidelines for the collection and handling of tumor tissue, to enhance the quality of samples for histopathological, IHC, genomic, and molecular analyses. These guidelines are fundamental in informing therapeutic decisions in cancer treatment.<BR><B>METHODS: </B>The guidelines were developed by a multidisciplinary panel of renowned specialists between June 12, 2013 and February 12, 2024. Initially, the panel deliberated on critical and controversial topics related to conducting precision medicine studies focusing on female tumors. Subsequently, 22 pivotal topics were identified within the framework and assigned to groups. These groups reviewed relevant literature and drafted preliminary recommendations. Following this, the recommendations were reviewed by the coordinators and received unanimous approval. Finally, the groups made the final adjustments, classified the level of evidence, and ranked the recommendations.<BR><B>CONCLUSIONS: </B>The collection of surgical samples requires minimum quality standards to enable histopathological, IHC, genomic, and molecular analyses. These analyses provide crucial data for informing therapeutic decisions, significantly impacting potential survival gains for patients with female tumors.